This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sanchez-Cespedes, M. Articles by Sidransky, D. Search for Related Content PubMed PubMed Citation Articles by Sanchez-Cespedes, M. Articles by Sidransky, D.

Molecular Detection of Neoplastic Cells in Lymph Nodes of Metastatic Colorectal Cancer Patients Predicts Recurrence¹

Department of Otolaryngology-Head and Neck Surgery, Division of Head and Neck Cancer Research [M. S-C., K. H., J. J., D. S.], Tumor Biology [M. E., J. G. H.), Pathology Department [W. H. W.], and Oncology Biostatistics [S. P.], The Johns Hopkins Oncology Center, Baltimore, Maryland 21205, and Neoprobe Corp., Dublin, Ohio [F. O. C.]

Disseminated disease, especially to the liver, constitutes the major risk of recurrence for colorectal cancer patients. However, successful resection can still be achieved in 25–35% of colorectal cancer patients with isolated metastases. To evaluate the clinical value of occult micrometastatic disease detection in lymph nodes, we tested genetic (K-ras and p53 gene mutations) and epigenetic (p16 promoter hypermethylation) molecular markers in the perihepatic lymph nodes from colorectal cancer patients with isolated liver metastases. DNA was extracted from 21 paraffin-embedded liver metastases and 80 lymph nodes from 21 colorectal cancer patients. K-ras and p53 gene mutations were identified in DNA from liver metastases by PCR amplification followed by cycle sequencing. A sensitive oligonucleotide-mediated mismatch ligation assay was used to search for the presence of K-ras and p53 mutations to detect occult disease in 68 lymph nodes from tumors positive for these gene mutations. Promoter hypermethylation at the p16 tumor suppressor gene was examined in both liver lesions and lymph nodes by methylation-specific PCR. Sixteen of the 21 (76%) liver metastases harbored either gene point mutations or p16 promoter hypermethylation. Twelve of the 68 lymph nodes were positive for tumor cells by molecular evaluation and negative for tumor cells by histopathology and cytokeratin immunohistochemistry, whereas none were positive for tumor cells by histopathology or negative for tumor cells by molecular analysis (P = 0.0005, McNemar’s test). Moreover, in three patients with lymph nodes that were histologically negative at all sites, molecular screening detected tumor DNA at one or more lymph nodes. Survival analysis showed a median survival of 1056 days for patients without evidence of lymph node involvement by molecular analysis and 165 days for patients with positive lymph nodes by this approach (P = 0.0005). These results indicate that lymph node metastasis screening in colorectal cancer patients by molecular-based techniques increases the sensitivity of tumor cell detection and can be a good predictor of recurrence in colorectal cancer patients with resectable liver metastases.

This article has been cited by other articles:

				F. M.A. Melfi, M. Lucchi, F. Davini, A. Viti, G. Fontanini, L. Boldrini, G. Boni, and A. Mussi Intraoperative sentinel lymph node mapping in stage I non-small cell lung cancer: detection of micrometastases by polymerase chain reaction. Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 181 - 186. [Abstract] [Full Text] [PDF]

				M. V. Brock, C. M. Hooker, E. Ota-Machida, Y. Han, M. Guo, S. Ames, S. Glockner, S. Piantadosi, E. Gabrielson, G. Pridham, et al. DNA Methylation Markers and Early Recurrence in Stage I Lung Cancer N. Engl. J. Med., March 13, 2008; 358(11): 1118 - 1128. [Abstract] [Full Text] [PDF]

				P. V. Korita, T. Wakai, Y. Shirai, J. Sakata, K. Takizawa, P. V. Cruz, Y. Ajioka, and K. Hatakeyama Intrahepatic Lymphatic Invasion Independently Predicts Poor Survival and Recurrences after Hepatectomy in Patients with Colorectal Carcinoma Liver Metastases Ann. Surg. Oncol., December 1, 2007; 14(12): 3472 - 3480. [Abstract] [Full Text] [PDF]

				Z. Liu, M. Jiang, J. Zhao, and H. Ju Circulating Tumor Cells in Perioperative Esophageal Cancer Patients: Quantitative Assay System and Potential Clinical Utility Clin. Cancer Res., May 15, 2007; 13(10): 2992 - 2997. [Abstract] [Full Text] [PDF]

				K Busby and A Morris Detection of BRAF mutations in colorectal tumours and peritoneal washings using a mismatch ligation assay J. Clin. Pathol., April 1, 2005; 58(4): 372 - 375. [Abstract] [Full Text] [PDF]

				N. Umetani, H. Takeuchi, A. Fujimoto, M. Shinozaki, A. J. Bilchik, and D. S. B. Hoon Epigenetic Inactivation of ID4 in Colorectal Carcinomas Correlates with Poor Differentiation and Unfavorable Prognosis Clin. Cancer Res., November 15, 2004; 10(22): 7475 - 7483. [Abstract] [Full Text] [PDF]

				M. Pellise, A. Castells, A. Gines, R. Agrelo, M. Sole, S. Castellvi-Bel, G. Fernandez-Esparrach, J. Llach, M. Esteller, J. M. Bordas, et al. Detection of Lymph Node Micrometastases by Gene Promoter Hypermethylation in Samples Obtained by Endosonography- Guided Fine-Needle Aspiration Biopsy Clin. Cancer Res., July 1, 2004; 10(13): 4444 - 4449. [Abstract] [Full Text] [PDF]

				J. G. Herman and S. B. Baylin Gene Silencing in Cancer in Association with Promoter Hypermethylation N. Engl. J. Med., November 20, 2003; 349(21): 2042 - 2054. [Full Text] [PDF]

				S. V. Harden, Y. Tokumaru, W. H. Westra, S. Goodman, S. A. Ahrendt, S. C. Yang, and D. Sidransky Gene Promoter Hypermethylation in Tumors and Lymph Nodes of Stage I Lung Cancer Patients Clin. Cancer Res., April 1, 2003; 9(4): 1370 - 1375. [Abstract] [Full Text] [PDF]

				R. J. Feezor, E. M. Copeland III, and S. N. Hochwald Significance of Micrometastases in Colorectal Cancer Ann. Surg. Oncol., December 1, 2002; 9(10): 944 - 953. [Full Text] [PDF]

				I M Frayling Methods of molecular analysis: mutation detection in solid tumours Mol. Pathol., April 1, 2002; 55(2): 73 - 79. [Abstract] [Full Text] [PDF]

				T. Etoh, H. Ueo, H. Inoue, K. Sato, T. Utsunomiya, G. F. Barnard, S. Kitano, and M. Mori Clinical Significance of K-Ras Mutations in Intraoperative Tumor Drainage Blood From Patients With Colorectal Carcinoma Ann. Surg. Oncol., June 1, 2001; 8(5): 407 - 412. [Abstract] [Full Text] [PDF]

				S. Tortola, R. Steinert, M. Hantschick, M. A. Peinado, I. Gastinger, P. Stosiek, H. Lippert, W. Schlegel, and M. A. Reymond Discordance Between K-ras Mutations in Bone Marrow Micrometastases and the Primary Tumor in Colorectal Cancer J. Clin. Oncol., June 1, 2001; 19(11): 2837 - 2843. [Abstract] [Full Text] [PDF]

				S. J. Clayton, F. M. Scott, J. Walker, K. Callaghan, K. Haque, T. Liloglou, G. Xinarianos, S. Shawcross, P. Ceuppens, J. K. Field, et al. K-ras Point Mutation Detection in Lung Cancer: Comparison of Two Approaches to Somatic Mutation Detection Using ARMS Allele-specific Amplification Clin. Chem., December 1, 2000; 46(12): 1929 - 1938. [Abstract] [Full Text] [PDF]